{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T06:22:53Z","timestamp":1791872573890,"version":"4.3.4"},"reference-count":33,"publisher":"BMJ","issue":"7","license":[{"start":{"date-parts":[[2025,7,27]],"date-time":"2025-07-27T00:00:00Z","timestamp":1753574400000},"content-version":"unspecified","delay-in-days":26,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Glob Health"],"accepted":{"date-parts":[[2025,7,1]]},"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>Poor-quality antimalarial medications, including falsified and substandard formulations, pose significant public health risks, contributing to ineffective treatment and potential drug resistance. Our research conducted in 2013 on Bioko Island, Equatorial Guinea (EG), found 9.6% (n=61) of the artemisinin-containing antimalarials (ACAs) purchased were of poor quality. This study aimed to update the quality of all sold antimalarials and extend to include regions on the mainland.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A total of 637 samples, 564 ACAs and 73 non-ACAs, were purchased from 424 outlets on Bioko Island and mainland EG using a mystery client sampling approach. Samples were analysed for content using high-performance liquid chromatography with diode-array detection and classified as acceptable, substandard or falsified based on pharmacopoeia tolerance limits. Additionally, bioavailability was assessed through dissolution testing for a select number of samples.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Overall, 40.5% of the samples were of acceptable quality, 31.2% were substandard and 28.3% were falsified. Regional differences showed a higher prevalence of falsified samples in Bata, Mangomo, Evinayong and Ebebiy\u00edn cities on the mainland (30.9%) compared with Bioko Island (25.6%). Artemether\/lumefantrine, the first-line treatment for malaria in EG, showed 25.7% were of acceptable quality, 48.2% substandard and 26.1% falsified. Artemisinin monotherapy tablets had the highest rate of falsification (56.8%). For non-ACAs, 13.3% of sulfadoxine\/pyrimethamine tablets were of acceptable quality, 48.9% substandard and 37.8% falsified. All quinine syrups were falsified, and most quinine tablets (87.5%) and injections (75.0%) were substandard.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>The prevalence of substandard and falsified antimalarials in EG has alarmingly increased from 9% in 2013 to 59.5% in 2018, highlighting the urgent need for enhanced regulatory measures. Immediate actions should include strengthening drug quality surveillance, particularly in private sector pharmacies, and implementing low-cost medicine screening methods for early detection of poor-quality medications. Ensuring the quality of antimalarials is critical to maintaining the efficacy of malaria control programmes and preventing the development of drug resistance.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/bmjgh-2024-018597","type":"journal-article","created":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T01:15:14Z","timestamp":1753665314000},"page":"e018597","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":3,"title":["Assessing the quality of antimalarial drugs in Equatorial Guinea: a follow-up study"],"prefix":"10.1136","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4959-0577","authenticated-orcid":false,"given":"Harparkash","family":"Kaur","sequence":"first","affiliation":[{"name":"Department of Clinical Research, London School of Hygiene and Tropical Medicine, London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Paris","sequence":"additional","affiliation":[{"name":"Health Protection Surveillance Centre (HPSC) 25-27 Middle Gardiner Street, Dublin, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerem\u00edas N","family":"Mba Eyono","sequence":"additional","affiliation":[{"name":"MCD Global Health, Malabo, Equatorial Guinea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Restituto Mba","family":"Nguema Avue","sequence":"additional","affiliation":[{"name":"MCD Global Health, Malabo, Equatorial Guinea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wonder P","family":"Phiri","sequence":"additional","affiliation":[{"name":"MCD Global Health, Malabo, Equatorial Guinea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan M","family":"Smith","sequence":"additional","affiliation":[{"name":"MCD Global Health, Silver Spring, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4069-9528","authenticated-orcid":false,"given":"Carlos A","family":"Guerra","sequence":"additional","affiliation":[{"name":"MCD Global Health, Silver Spring, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matilde","family":"Riloha Rivas","sequence":"additional","affiliation":[{"name":"National Malaria Control Programme, Malabo, Equatorial Guinea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo A","family":"Garc\u00eda","sequence":"additional","affiliation":[{"name":"MCD Global Health, Silver Spring, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,7,27]]},"reference":[{"key":"2025072718150788000_10.7.e018597.1","first-page":"505","article-title":"Falsified antimalarials: a minireview","volume":"13","author":"Chaccour","year":"2015","journal-title":"Expert Rev Anti Infect Ther"},{"key":"2025072718150788000_10.7.e018597.2","unstructured":"Who health organization . Malaria. Available: https:\/\/www.who.int\/activities\/treating-malaria [Accessed 5 Nov 2024]."},{"key":"2025072718150788000_10.7.e018597.3","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2016.1187134"},{"key":"2025072718150788000_10.7.e018597.4","unstructured":"Who health organization . 1 in 10 medical products in developing countries is substandard or falsified. Available: https:\/\/www.who.int\/news\/item\/28-11-2017-1-in-10-medical-products-in-developing-countries-is-substandard-or-falsified [Accessed 27 Sep 2024]."},{"key":"2025072718150788000_10.7.e018597.5","unstructured":"Multisource (generic) pharmaceutical products: guidelines on registration requirements to establish interchangeability. Available: https:\/\/www.gmp-compliance.org\/files\/guidemgr\/who_trs1003_annex6.pdf"},{"key":"2025072718150788000_10.7.e018597.6","unstructured":"Malaria. Available: https:\/\/www.who.int\/data\/gho\/data\/themes\/malaria [Accessed 6 Nov 2024]."},{"key":"2025072718150788000_10.7.e018597.7","doi-asserted-by":"crossref","unstructured":"Chaccour CJ , Kaur H , Mabey D , et al . Travel and fake artesunate: a risky business. Lancet 2012;380. doi:10.1016\/S0140-6736(12)60649-7","DOI":"10.1016\/S0140-6736(12)60649-7"},{"key":"2025072718150788000_10.7.e018597.8","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s12936-023-04504-7","article-title":"Identifying individual, household and environmental risk factors for malaria infection on Bioko Island to inform interventions","volume":"22","author":"Garc\u00eda","year":"2023","journal-title":"Malar J"},{"key":"2025072718150788000_10.7.e018597.9","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijid.2024.107197","article-title":"Malaria burden and residual transmission: two thirds of mosquito bites may not be preventable with current vector control tools on Bioko Island, Equatorial Guinea","volume":"147","author":"Ooko","year":"2024","journal-title":"Int J Infect Dis"},{"key":"2025072718150788000_10.7.e018597.10","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s12936-018-2213-9","article-title":"Trends in parasite prevalence following 13 years of malaria interventions on Bioko island, Equatorial Guinea: 2004-2016","volume":"17","author":"Cook","year":"2018","journal-title":"Malar J"},{"key":"2025072718150788000_10.7.e018597.11","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-10339-1"},{"key":"2025072718150788000_10.7.e018597.12","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1186\/s12936-015-0986-7","article-title":"Malaria prevalence in Bata district, Equatorial Guinea: a cross-sectional study","volume":"14","author":"Ncogo","year":"2015","journal-title":"Malar J"},{"key":"2025072718150788000_10.7.e018597.13","doi-asserted-by":"crossref","DOI":"10.3390\/tropicalmed8030149","article-title":"Effects of Age, Gender and Soil-Transmitted Helminth Infection on Prevalence of Plasmodium Infection among Population Living in Bata District, Equatorial Guinea","volume":"8","author":"Me\u00f1e","year":"2023","journal-title":"Trop Med Infect Dis"},{"key":"2025072718150788000_10.7.e018597.14","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgh-2017-000409","article-title":"Prevalence of substandard and falsified artemisinin-based combination antimalarial medicines on Bioko Island, Equatorial Guinea","volume":"2","author":"Kaur","year":"2017","journal-title":"BMJ Glob Health"},{"key":"2025072718150788000_10.7.e018597.15","unstructured":"WHO Expert Committee on Specifications for Pharmaceutical Preparations . Guidelines on the conduct of surveys of the quality of medicines. who technical report series no. 996. 2016. Available: https:\/\/www.who.int\/publications\/m\/item\/ Annex-7-trs-no-966 [Accessed 1 Nov 2023]."},{"key":"2025072718150788000_10.7.e018597.16","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000052","article-title":"Guidelines for field surveys of the quality of medicines: a proposal","volume":"6","author":"Newton","year":"2009","journal-title":"PLoS Med"},{"key":"2025072718150788000_10.7.e018597.17","doi-asserted-by":"crossref","DOI":"10.1186\/s12936-017-1852-6","article-title":"Anti-malarial medicine quality field studies and surveys: a systematic review of screening technologies used and reporting of findings","volume":"16","author":"Lalani","year":"2017","journal-title":"Malar J"},{"key":"2025072718150788000_10.7.e018597.18","doi-asserted-by":"crossref","DOI":"10.1186\/1475-2875-13-46","article-title":"Communicating the AMFm message: exploring the effect of communication and training interventions on private for-profit provider awareness and knowledge related to a multi-country anti-malarial subsidy intervention","volume":"13","author":"Willey","year":"2014","journal-title":"Malar J"},{"key":"2025072718150788000_10.7.e018597.19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0007270","article-title":"Simple field assays to check quality of current artemisinin-based antimalarial combination formulations","volume":"4","author":"Loset","year":"2009","journal-title":"PLoS ONE"},{"key":"2025072718150788000_10.7.e018597.20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0125577","article-title":"Quality of artemisinin-based combination formulations for malaria treatment: prevalence and risk factors for poor quality medicines in public facilities and private sector drug outlets in Enugu, Nigeria","volume":"10","author":"Kaur","year":"2015","journal-title":"PLoS One"},{"key":"2025072718150788000_10.7.e018597.21","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s12936-016-1096-x","article-title":"Fake anti-malarials: Start with the facts: meeting report summary","volume":"15","author":"Kaur","year":"2016","journal-title":"Malar J"},{"key":"2025072718150788000_10.7.e018597.22","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.15-0221"},{"key":"2025072718150788000_10.7.e018597.23","doi-asserted-by":"crossref","DOI":"10.1186\/1475-2875-10-352","article-title":"Poor quality vital anti-malarials in Africa - an urgent neglected public health priority","volume":"10","author":"Newton","year":"2011","journal-title":"Malar J"},{"key":"2025072718150788000_10.7.e018597.24","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.14-0343"},{"key":"2025072718150788000_10.7.e018597.25","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.14-0391"},{"key":"2025072718150788000_10.7.e018597.26","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1080\/14787210.2016.1187560","article-title":"A link between poor quality antimalarials and malaria drug resistance?","volume":"14","author":"Newton","year":"2016","journal-title":"Expert Rev Anti Infect Ther"},{"key":"2025072718150788000_10.7.e018597.27","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.mehy.2017.12.018","article-title":"The role of antimalarial quality in the emergence and transmission of resistance","volume":"111","author":"Brock","year":"2018","journal-title":"Med Hypotheses"},{"key":"2025072718150788000_10.7.e018597.28","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2018.1662","article-title":"Prevalence and Estimated Economic Burden of Substandard and Falsified Medicines in Low- and Middle-Income Countries: A Systematic Review and Meta-analysis","volume":"1","author":"Ozawa","year":"2018","journal-title":"JAMA Netw Open"},{"key":"2025072718150788000_10.7.e018597.29","unstructured":"Faucon B , Murphy C , Whalen J . Africa\u2019s malaria battle: fake drug pipeline undercuts progress. Wall Street Journal; 2013. Available: http:\/\/online.wsj.com\/article\/SB10001424127887324474004578444942841728204.html [Accessed 10 Oct 2024]."},{"key":"2025072718150788000_10.7.e018597.30","unstructured":"WHO policy brief for the implementation of intermittent preventive treatment of malaria in pregnancy using sulfadoxine-pyrimethamine (iptp-sp). Available: https:\/\/www.who.int\/publications\/i\/item\/WHO-HTM-GMP-2014.4 [Accessed 1 Nov 2024]."},{"key":"2025072718150788000_10.7.e018597.31","unstructured":"Who health organization . WHO policy brief for the implementation of intermittent preventive treatment of malaria in pregnancy using sulfadoxine-pyrimethamine (iptp-sp). Available: https:\/\/www.afro.who.int\/sites\/default\/files\/2017-06\/iptp-sp-updated-policy-brief-24jan2014.pdf"},{"key":"2025072718150788000_10.7.e018597.32","doi-asserted-by":"crossref","first-page":"947","DOI":"10.4269\/ajtmh.19-0966","article-title":"The Equatoguinean Malaria Vaccine Initiative: From the Launching of a Clinical Research Platform to Malaria Elimination Planning in Central West Africa","volume":"103","author":"Billingsley","year":"2020","journal-title":"Am J Trop Med Hyg"},{"key":"2025072718150788000_10.7.e018597.33","doi-asserted-by":"crossref","DOI":"10.1080\/20523211.2024.2375267","article-title":"Prevalence of substandard, falsified, unlicensed and unregistered medicine and its associated factors in Africa: a systematic review","volume":"17","author":"Asrade Mekonnen","year":"2024","journal-title":"J Pharm Policy Pract"}],"container-title":["BMJ Global Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjgh-2024-018597","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T01:15:21Z","timestamp":1753665321000},"score":1,"resource":{"primary":{"URL":"https:\/\/gh.bmj.com\/lookup\/doi\/10.1136\/bmjgh-2024-018597"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":33,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7,27]]},"published-print":{"date-parts":[[2025,7]]}},"alternative-id":["10.1136\/bmjgh-2024-018597"],"URL":"https:\/\/doi.org\/10.1136\/bmjgh-2024-018597","relation":{},"ISSN":["2059-7908"],"issn-type":[{"value":"2059-7908","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7]]}}}